Jul 18 |
Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine
|
Jul 17 |
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
|
Jul 17 |
3 No-Brainer Stocks to Buy With $200 Right Now
|
Jul 12 |
U.S. Senate passes bill to trim Big Pharma "patent thickets"
|
Jul 10 |
Argus upgrades Teva to buy, cites recent drug approvals
|
Jul 10 |
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
|
Jul 2 |
Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024
|
Jul 2 |
FTC investigates Teva over contested product patents
|
Jul 1 |
Update: Market Chatter: Teva Pharmaceuticals Faces FTC Probe on Patent Listings
|
Jul 1 |
Correction: Top Midday Stories: Boeing to Acquire Spirit AeroSystems; Robinhood Acquires Pluto; FTC Probes Teva; BlackRock Acquires Preqin; SCOTUS Grants Trump Some Immunity
|